Trial Profile
Prospective, Multi-national, Multicentre, Non-interventional Study to Evaluate the Long Term Safety of Esmya, in Particular Endometrial Safety, and the Current Prescription and Management Patterns of Esmya in a Long Term Treatment Setting.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Ulipristal (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Acronyms Premium
- Sponsors PregLem
- 15 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 New trial record